Impact of a multifaceted prevention program on ventilator-associated pneumonia including selective oropharyngeal decontamination

C. Landelle1,2, V. Nocquet Boyer3, M. Abbas1, E. Genevois3, N. Abidi3, S. Naimo3, R. Raulais3, L. Bouchoud4, F. Boroli3, H. Terrisse2, J.-L. Bosson2, S. Harbarth1 and J. Pugin3*

© 2018 The Author(s)

Abstract
Purpose: We describe the impact of a multifaceted program for decreasing ventilator-associated pneumonia (VAP) after implementing nine preventive measures, including selective oropharyngeal decontamination (SOD).

Methods: We compared VAP rates during an 8-month pre-intervention period, a 12-month intervention period, and an 11-month post-intervention period in a cohort of patients who received mechanical ventilation (MV) for > 48 h. The primary objective was to assess the effect on first VAP occurrence, using a Cox cause-specific proportional hazards model. Secondary objectives included the impact on emergence of antimicrobial resistance, antibiotic consumption, duration of MV, and ICU mortality.

Results: Pre-intervention, intervention and post-intervention VAP rates were 24.0, 11.0 and 3.9 VAP episodes per 1000 ventilation-days, respectively. VAP rates decreased by 56% [hazard ratio (HR) 0.44, 95% CI 0.29–0.65; P < 0.001] in the intervention and by 85% (HR 0.15, 95% CI 0.08–0.27; P < 0.001) in the post-intervention periods. During the intervention period, VAP rates decreased by 42% (HR 0.58, 95% CI 0.38–0.87; P < 0.001) after implementation of eight preventive measures without SOD, and by 70% after adding SOD (HR 0.30, 95% CI 0.13–0.72; P < 0.001) compared to the pre-intervention period. The incidence density of intrinsically resistant bacteria (to colistin or tobramycin) did not increase. We documented a significant reduction of days of therapy per 1000 patient-days of broad-spectrum antibiotic used to treat lower respiratory tract infection (P < 0.028), median duration of MV (from 7.1 to 6.4 days; P < 0.003) and ICU mortality (from 16.2 to 13.5%; P < 0.049) for patients ventilated > 48 h between the pre- and post-intervention periods.

Conclusions: Our preventive program produced a sustained decrease in VAP incidence. SOD provides an additive value.

Keywords: Ventilator-associated pneumonia, Multimodal strategy, Selective oropharyngeal decontamination, Intensive care unit

*Correspondence: jerome.pugin@unige.ch
3 Division of Intensive Care, University Hospitals of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland
Full author information is available at the end of the article
Introduction

Ventilator-associated pneumonia (VAP) remains a serious complication of mechanical ventilation (MV), and has an incidence between 2 and 16 episodes per 1000 ventilator-days [1], an attributable mortality of 5–13% [2], excess ICU length of stay (LOS) for survivors up to 9 days [3], and extra costs [4].

Many studies have reported decreased VAP rates associated with the use of bundles of preventive measures [5]. Fewer studies have reported compliance with preventive measures [6–16] and explored sustainability of interventions after implementation [7, 10–13, 16–19]. Except for one [19], studies have not reported results of a bundle including selective oropharyngeal decontamination (SOD).

SOD consists in the application of topical antibiotics to the oropharynx, without enteral or intravenous antibiotics. There is a significant reduction of VAP in studies which investigated decontamination with antibiotic agents [risk ratio (RR): 0.27; 95% confidence intervals (CI) 0.18–0.42] but no effect on all-cause mortality, duration of ventilation, or duration of ICU stay [20]. A recent meta-analysis including four randomized controlled trials (RCTs) demonstrated a beneficial effect of SOD on mortality [21]. Promoting bacterial resistance with SOD remains a serious concern, although a recent meta-analysis did not detect an increased incidence of antimicrobial resistant pathogens in recipients of selective decontamination compared with non-recipients [22].

The primary objective of this prospective, interventional single-center cohort study was to determine the impact of implementing a multifaceted VAP prevention program on VAP rates. Secondary objectives were to determine the impact of SOD on VAP rates, to evaluate emergence of antimicrobial resistant pathogens in recipients of selective decontamination compared with non-recipients [22].

Methods

Setting

Geneva University Hospital is a 1900-bed hospital serving as a primary and tertiary care facility in Geneva, Switzerland. The mixed medical–surgical adult ICU has 34 beds, employs 250 nursing and medical staff members, and admits 2400 patients per year on average. The nurse–patient and nursing assistant–patient ratios are 1:2 and 1:4, respectively, with little difference across shifts or over time. Neither the structure nor the staffing of the ICU was modified during the study. As a quality improvement project, ethics committee approval was not required.

Design

This study used a quasi-experimental, uncontrolled, before-and-after design to analyze the effects of implementing a VAP prevention bundle. For the present study, the pre-intervention period comprised 8 months from January through August 2014, the intervention period 12 months from September 2014 through August 2015, and the post-intervention period (follow-up) 11 months from September 2015 through July 2016.

VAP surveillance

Surveillance of VAP was performed in our ICU since January 2014, and included all patients with MV > 48 h (endotracheal tube or tracheostomy), including the following variables for each included patient: age, sex, severity of illness as assessed using the Simplified Acute Physiology Score II [23], main reason for ICU admission, dates of ventilation, presence of VAP, date of VAP onset, Clinical Pulmonary Infection Score (CPIS) [24], diagnostic method for VAP [bronchoalveolar lavage (BAL) or mini-bronchoalveolar lavage (mini-BAL)], microorganisms identified, dates of ICU admission and discharge, and mortality.

Probable VAP was defined as the presence of (1) radiologic changes with systemic inflammation (temperature ≥ 38 °C, or leukocyte count > 12,000 or < 4000 cells/mL) with clinical pulmonary signs (i.e. purulent tracheal secretions) according to the criteria established by Hospitals in Europe Linked for Infection Control through Surveillance [25], and (2) a CPIS > 6 [24]. Definite VAP was defined by the addition of positive quantitative cultures of distal pulmonary sampling obtained by BAL (significant threshold ≥ 10^4 colony-forming units/mL) or mini-BAL (significant threshold ≥ 10^3 colony-forming units/mL). VAP was defined as early-onset when it developed in the first 4 days of MV, and as late-onset when it occurred after 4 days of MV.

Screening, data collection and reporting were conducted by the same ICU staff throughout the surveillance period and diagnosis of VAP was made independently by two investigators following a consensus meeting.

Multifaceted prevention program

A multidisciplinary task force, consisting of intensivists, ICU nurses, pharmacists, infection control and infectious
Antimicrobial resistance

Antimicrobial resistance was evaluated throughout the project period, albeit via different methods. From January 2014 to April 2015, monthly point-prevalence studies of intestinal carriage of Gram-negative resistant bacteria were performed on all ICU patients. As of May 2015, we performed targeted screening of patients who received SOD, once the SOD was discontinued. An additional ecological analysis of all clinical or screening bacterial isolates from the ICU was performed by calculating incidence densities (per 1000 patient-days) for bacteria intrinsically resistant to either colistin or tobramycin. Detailed methods and microbiological techniques are reported in the Supplementary Appendix.

Antibiotic consumption

Total antibiotic consumption, and consumption of broad-spectrum antibiotics that are used for the treatment of lower respiratory tract infection (LRTI), were analyzed for each period (Supplementary Appendix).

Other measures

Other measures in our ICU are reported in the Supplementary Appendix.

Statistical analyses

Baseline characteristics were described by frequencies, medians and interquartile range (IQR). Groups were compared by means of the Mann–Whitney U test, the Kruskal–Wallis test, and Independent Samples Median Test, Pearson Chi-squared test or Fisher’s exact test as appropriate for continuous and categorical variables.

All VAP episodes (definite and probable) were included. We computed the number of first VAP episodes per 1000 ventilator-days at risk (until VAP diagnosis or extubation). We also computed (1) the total number of VAP episodes per 1000 ventilator-days, including all ventilation sessions, (2) the proportion of patients with VAP among patients receiving ventilation for >48 h, and (3) the time to the first VAP episode. Only patients who received MV for >48 h were included in the analysis.

We analyzed the effect of the intervention (with and without SOD) on the incidence of first VAP episodes by segmented regression analysis using a Poisson model [27]. In this analysis, incidence rate ratios (IRR) were computed per months before, during, and after the intervention. The model included an intercept (mean VAP rate at study initiation) and three main period effects (before–during intervention without SOD, during intervention without SOD–during intervention with SOD and during intervention with SOD–after intervention).

The risk of first VAP over time was also analyzed using a competing-risks survival approach comparing the time to first VAP, with death and ICU discharge being competing events [28]. The association between periods and VAP risk was tested using a Cox proportional cause-specific hazards model. The cumulative cause-specific hazard of VAP was estimated for each study period. We determined the empirical daily hazard rate for VAP and the hazard function from the Cox model to estimate the event rate per day. The results were presented as cause-specific hazard ratios (HR) with 95%CI.
All statistical tests were two-tailed and a \( P \) value \( \leq 0.05 \) was considered statistically significant. Statistical analysis was performed with PASW v.23 (SPSS, Chicago, IL, USA), and STATA v.13.1 (Stata, College Station, TX, USA).

**Results**

Of the 6287 admissions during the study period, 2991 were followed by ICU stays > 48 h. These 2991 admissions comprised 1262 sessions of MV for > 48 h, for a total of 10,825 ventilation-days: 318 sessions of MV (3128 ventilation-days).
ventilation-days) during the pre-intervention, 507 sessions (4234 ventilation-days) during the intervention, and 437 sessions (3463 ventilation-days) during the post-intervention period.

Table 1 lists the characteristics of included patients during each period. Patients did not differ significantly with respect to age, sex, SAPS II, and main reason for ICU admission.

Compliance with preventive measures
A total of 73, 1224 and 695 evaluations of hand hygiene and 223, 2042 and 632 evaluations of other preventive measures were performed for the pre-intervention, intervention and post-intervention periods, respectively (Fig. 1; e-Table 1). As shown in Fig. 1, hand-hygiene compliance was initially 56.2%, increased in the intervention period (67%) and remained stable over time (65.5%). Global compliance with all other preventive measures was initially high (60%), and increased significantly in the intervention (80%) and post-intervention (83.3%) periods. Compliance with each preventive measure increased significantly between each period and between the pre-intervention and each of the two subsequent periods, except for oral hygiene that significantly decreased in the post-intervention period compared to the intervention period (83.7 to 79.3%).

Total VAP rates
The incidence density rates were 21.4, 10.6, and 3.8 during the pre-intervention, intervention, and post-intervention periods, respectively, with significant differences between the three periods (Table 2).

First VAP rate
The proportions of patients with at least one VAP episode among patients who received ventilation for >48 h were 20.1, 8.5, and 3% during the pre-intervention, intervention, and post-intervention periods, respectively ($P<0.001$) (Table 2). The incidence density rates of first VAP episodes per 1000 ventilation-days were 24.0 during the pre-intervention period, 11.0 during the intervention period and 3.9 during the post-intervention period. VAP rates decreased by 54% in the intervention (relative risk, 0.46, 95% CI 0.31–0.67; $P<0.05$) and by 84% in the

### Table 2 Characteristics and outcomes of patients who received mechanical ventilation for >48 h

| Variable                                             | Pre-intervention period | Intervention period | Post-intervention period |
|------------------------------------------------------|-------------------------|---------------------|--------------------------|
| Sessions of mechanical ventilation                  | 318                     | 507                 | 437                      |
| Total ventilator-days                                | 3128                    | 4234                | 3463                     |
| Ventilator-days at risk                              | 2667                    | 3920                | 3381                     |
| Total VAP episodes                                   | 67                      | 45                  | 13                       |
| First VAP episodes                                   | 64 (20.1%)              | 43 (8.5%)$^a$       | 13 (3%)$^{bcd}$           |
| Early onset                                          | 25 (39.1%)              | 22 (51.2%)          | 4 (30.8%)                |
| Late onset                                           | 39 (60.9%)              | 21 (48.8%)          | 9 (69.2%)                |
| Diagnosed by bronchoalveolar lavage                  | 10 (15.6%)              | 6 (14%)             | 4 (30.8%)                |
| Diagnosed by mini-bronchoalveolar lavage             | 34 (53.1%)              | 34 (79.1%)$^a$      | 7 (53.8%)$^d$            |
| Probable                                             | 28 (43.8%)              | 5 (11.6%)$^a$       | 2 (15.4%)$^d$            |
| Definite                                             | 36 (56.2%)              | 38 (88.4%)          | 11 (84.6%)               |
| Total VAP incidence density rates per 1000 ventilator-days at risk (95% CI) | 21.4 (16.3–26.6) | 10.6 (7.5–13.7)$^a$ | 3.8 (1.7–5.8)$^{bcd}$ |
| First VAP incidence density rates per 1000 ventilator-days at risk (95% CI) | 24.0 (18.1–29.9) | 11.0 (7.7–14.2)$^a$ | 3.9 (1.8–5.9)$^{bcd}$ |
| First probable VAP incidence density rates per 1000 ventilator-days at risk (95% CI) | 10.5 (6.6–14.4) | 1.3 (0.2–2.4) | 0.6 (0.2 to 1.4) |
| First definite VAP incidence density rates per 1000 ventilator-days at risk (95% CI) | 13.5 (9.1–17.9) | 9.7 (6.6–12.8) | 3.3 (1.3–5.2) |
| Clinical Pulmonary Infection Score for VAP episodes, median (IQR) | 8 (7–9) | 8 (7–9) | 8 (7–8) |
| Duration of mechanical ventilation for all mechanical ventilation sessions, median days (IQR) | 7.14 (4.61–11.06) | 6.50 (4.17–9.85)$^a$ | 6.35 (4.15–9.74)$^{cd}$ |

Data are no. (%) of patients, unless otherwise indicated
CI confidence interval, IQR interquartile range, VAP ventilator-associated pneumonia

$^a$ Significant $P$ value between the pre-intervention and intervention periods

$^b$ Significant $P$ value between the intervention and post-intervention periods

$^c$ Significant $P$ value between the pre-intervention and post-intervention periods

$^d$ Significant $P$ value between the three periods
post-intervention periods (relative risk, 0.16, 95% CI 0.1–0.27; \( P < 0.05 \)) compared to the pre-intervention period. The median time to first VAP was 5.3 days (IQR 3.7–7.5) during the pre-intervention period 4.8 days (IQR 3.3–8.1) during the intervention period and 6.3 days (IQR 4.3–10.2) during the post-intervention period without significant differences.

The distribution of microorganisms associated with the first VAP episodes is reported in e-Table 2. There was a trend towards a decrease of Gram-negative bacilli and a relative increase of Gram-positive cocci over the study period.

Before the fifth ventilator-day, 25 (7.9% of patients receiving ventilation) first VAP episodes were identified during the pre-intervention period, 22 (4.3%) during the intervention period and 4 (0.9%) during the post-intervention period (Table 2). After the fifth ventilator-day, 39 (12.3% of patients still receiving ventilation on day 4), 21 (4.1%) and 9 (2.1%) first VAP episodes were identified during the pre-intervention, intervention and post-intervention periods, respectively. Probable VAP decreased significantly between the pre-intervention and intervention periods.

Additive effect of SOD

The results of the segmented regression analysis are shown in Fig. 2. Before the intervention, VAP incidence density was high and remained stable over time. The intervention without SOD was associated with a decrease of 42% in VAP rates (IRR 0.58, 95% CI 0.45–0.74). The implementation of SOD was associated with a further decrease of 70% in VAP rates (IRR 0.30, 95% CI 0.18–0.48). After the intervention, VAP incidence density was low and remained stable over time.

The results of the cumulative hazard of first VAP according to periods and daily hazard of first VAP are shown in Fig. 3a, b. The intervention decreased the VAP incidence rate by 56% (HR 0.44, 95% CI 0.29–0.65; \( P < 0.001 \)). The intervention without SOD was associated with a significant decrease of 42% (HR 0.58, 95% CI 0.38–0.87; \( P < 0.001 \)) in VAP incidence rates in comparison with baseline. SOD was associated with a significant decrease of 70% (HR 0.30, 95% CI 0.13–0.72; \( P < 0.001 \)) in VAP incidence rates over time in comparison with intervention without SOD. Post-intervention was associated with a non-significant decrease of 12% (HR 0.88, 95% CI 0.33–2.32; \( P > 0.05 \)) in VAP incidence rates over time in comparison with pre-intervention. Globally, post-intervention was associated with a significant decrease of 85% (HR 0.15, 95% CI 0.08–0.28; \( P < 0.001 \)) in VAP incidence rates over time in comparison with pre-intervention.

During the pre-intervention period, daily VAP hazard rates were 4.9, and 4.4% during the fifth and tenth days of MV, respectively. During the intervention without SOD, corresponding rates were 2.4 and 1.4%, respectively. During the intervention period with SOD, corresponding rates were 1.9 and 0%, respectively. During the post-intervention period, corresponding rates were 0.7 and 1.04%, respectively. The differences were statistically significant between periods only during the fifth days of MV (\( P = 0.03 \)).

There was no increase in antibiotic resistance, and colistin MIC did not increase after the introduction of SOD (Supplementary Appendix).

Antibiotic consumption

Total consumption of antibiotics did not change significantly between periods. However, we observed a significant decrease in the consumption of antibiotics used for treating LRTI in the post-intervention period compared to the pre-intervention period (Supplementary Appendix and e-Fig. 4).

Other outcome measures

A significant decrease was observed between the pre-intervention and intervention periods and between the pre-intervention and post-intervention periods for the median duration of MV among included study subjects, 7.14, 6.5 and 6.35 days, respectively (Table 2), and for ICU mortality, 16.2, 10.4 and 13.5%, respectively (Table 1).
Fig. 3  Cumulative cause-specific hazard (a) and daily hazard rates (b) of ventilator-associated pneumonia in the pre-intervention period, the intervention period without SOD, implementation of SOD and the post-intervention period using Cox proportional cause-specific hazard regression. a, b Blue lines represent the pre-intervention period, red lines the intervention period without SOD, gray lines the period after implementation of SOD, green lines the post-intervention period. b Dashed lines empirical daily hazard of VAP; solid lines smoothed hazard function.
The ICU LOS did not significantly differ between periods (Table 1). Knowledge of HCWs are described in the Supplementary Appendix.

Discussion
Our data suggest that the introduction of a multifaceted prevention program on VAP was associated with an important and sustained reduction in the incidence of VAP. SOD provides an additive effect.

Our initial VAP rate was higher than is usually reported in multicenter surveillance networks but similar to other settings that used comparable VAP definitions and surveillance methods, and included only patients who received MV for at least 48 h [8, 17]. Our multifaceted prevention program resulted in an 85% decrease in VAP rates. This large reduction effect, rarely described in the prevention program, resulted in an 85% decrease in VAP of MV or mortality [30, 31]. Despite a high initial global compliance with all the preventive measures (60%), global compliance increased in the post-intervention period (83.3%).

We attributed part of the success of the intervention to SOD; the intervention without SOD was associated with a significant decrease of 42% in VAP incidence rates and SOD added a further 28% in reduced VAP rates. We cannot exclude that SOD may have decreased microbiological yield in tracheal aspirates, artificially decreasing the number of probable VAP. We also cannot exclude that SOD truly “sterilized” the oropharyngeal fluid, preventing the transition from airway colonization to lung infection. A decreased rate of the incidence density of first definite VAP episodes was also observed across periods, and may favor this latter hypothesis. Accurately predicting the probability of ventilation for more than 2 days (criteria for SOD prescription in our study) was challenging in clinical practice, and this uncertainty may have lowered the number of SOD-eligible patients. Nevertheless, intensivists improved their predictive capacity during the study. Consequently, SOD compliance increased over time but the low level of compliance (51% in the intervention and 66% in the post-intervention period) could have minimized the additive value of SOD on VAP rates. Conversely, we observed a decrease in the duration of MV after the introduction of the bundle. Such a reduction could possibly be due to the decrease in VAP rates but also to better adherence to the sedation and weaning components of the multifaceted prevention program. This reduction in the duration of MV may also partially explain the decrease in the VAP rates.

Current evidence suggests that antibiotic resistance may decrease with the use of selective decontamination, although much of these data come from the Netherlands, an area with low endemic antibiotic resistance [22]. The present study was performed in a setting with a higher baseline prevalence of antimicrobial resistance [32, 33]. We did not observe an increase in antimicrobial selection pressure. No definite conclusion can be drawn about the selective pressure of SOD, as the methods of detection of emerging antimicrobial resistance were different throughout the project, and as rectal swabs were performed only once at the end of SOD administration, and not repeated over time, for example at ICU discharge. Of note, the relative proportion of Gram-positive cocci causing VAP increased in the post-intervention period, due to a substantial decrease in the proportion of Gram-negative bacilli.

Our study has several limitations. First, we did not use a randomized study design or a concurrent control group. Therefore, the exact impact of our prevention program on VAP rates may be difficult to assess. Second, our study was not blinded, and it is well known that VAP definitions carry some subjectivity. However, the methodology
of VAP diagnosis did not change over time. Third, compliance with preventive measures was not evaluated for each patient and each day. Determining which individual components of our multifaceted intervention, except SOD, led to its success was not possible. Because of a possible Hawthorne effect, we cannot affirm that compliance was similar during the non-observation periods. However, the performance assessments were conducted with the same methodology, the magnitude of improvement was sufficiently high to ascertain real changes, and our program produced sustained VAP rate decreases in the long term (e-Fig. 5). Fourthly, our study was performed in a single center. Whether the implementation of our program or data collection procedures can be generalized to other ICUs remains to be determined. Finally, a possible effect of regression to the mean, due to initially high VAP rates, cannot be excluded, but is unlikely to be responsible for the totality of the decrease.

In conclusion, we have demonstrated that simple preventive measures including SOD, surveillance and feedback, and education can significantly decrease VAP rates, duration of MV, and mortality. However, long-term use of SOD implies continuous surveillance of the emergence and selection of antimicrobial resistance.

Electronic supplementary material
The online version of this article (https://doi.org/10.1007/s00134-018-5227-4) contains supplementary material, which is available to authorized users.

Author details
1 Infection Control Program and WHO Collaborating Center, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland. 2 University Grenoble Alpes/CNRS, TEMAS TIM-C, UMR 5525, Grenoble, France. 3 Division of Intensive Care, University Hospitals of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland. 4 Division of Pharmacy, University Hospitals of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Acknowledgements
We thank the ICU team who participated in this quality improvement project. We are also indebted to all members of the bacteriology laboratory and infection control unit who helped with this project. This study was partially supported by an unrestricted, internal grant from the Department of Anesthesiology, Intensive Care, and Pharmacology, University Hospitals of Geneva, Switzerland.

Authors’ contributions
Design and conduct of the study: C. Landelle, V. Nocquet Boyer, M. Abbas, S. Harbarth and J. Pugin. Collection of the data: C. Landelle, V. Nocquet Boyer, M. Abbas, E. Genevois, N. Abidi, S. Naimo, R. Raulais, and F. Bordi. Management, analysis and interpretation of the data: C. Landelle, V. Nocquet Boyer, M. Abbas, L. Bouchoud, H. Terrisse, J.-L. Bosson, S. Harbarth, and J. Pugin. Manuscript preparation: C. Landelle, V. Nocquet Boyer, M. Abbas, H. Terrisse, S. Harbarth, and J. Pugin. Critical revision and approval of the manuscript: All authors.

Compliance with ethical standards

Conflict of interest
SH reports having received a peer-reviewed research grant funded by Pfizer; he is also a temporary member of the advisory boards of DNA Electronics, Bayer and Novartis. All other authors: none to declare.

Research involving human participants
As a quality improvement project, ethics committee approval was not required.

Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Received: 6 February 2018 Accepted: 11 May 2018 Published online: 21 October 2018

References
1. Barbier F, Andremont A, Wolff M, Bouadma L (2013) Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 19:216–228
2. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT et al (2013) Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 13:665–671
3. Kollef MH, Hamilton CW, Ernst FR (2012) Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 33:250–256
4. Hugonnet S, Eggmann P, Borst F, Marrocin P, Chevrolet JC, Pittet D (2004) Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol 25:1090–1096
5. Klomps M (2010) Ventilator-associated pneumonia: is zero possible? Clin Infect Dis 51:1123–1126
6. Bouadma L, Mouvillier B, Deile V, Le Corre B, Lolom I, Regnier B et al (2010) A multifaceted program to prevent ventilator-associated pneumonia: impact on compliance with preventive measures. Crit Care Med 38:789–796
7. Rello J, Alonso E, Lisboa T, Ricart M, Balsera B, Rovira A et al (2013) A care bundle approach for prevention of ventilator-associated pneumonia. Clin Microbiol Infect. 19:363–369
8. Morris AC, Hay AW, Swann DG, Everingham K, McCulloch C, McNulty J et al (2011) Reducing ventilator-associated pneumonia in intensive care: impact of implementing a care bundle. Crit Care Med 39:2218–2224
9. Sedwick MB, Lance-Smith M, Reeder SJ, Nardj J (2012) Using evidence-based practice to prevent ventilator-associated pneumonia. Crit Care Nurse 32:41–51
10. Khan R, Al-Dorzi HM, Al-Attas K, Ahmed FW, Mariné AM, Mundekakadan S et al (2016) The impact of implementing multifaceted interventions on the prevention of ventilator-associated pneumonia. Am J Infect Control 44:320–326
11. Rawat N, Yang T, Al IKJ, Catanzaro M, Cohen MD, Farley DO et al (2017) Two-state collaborative study of a multifaceted intervention to decrease ventilator-associated events. Crit Care Med 45:1208–1215
12. Berenholtz SM, Pham JC, Thompson DA, Needham DM, Lubomski LH, Hyzy RC et al (2011) Collaborative cohort study of an intervention to reduce ventilator-associated pneumonia in the intensive care unit. Infect Control Hosp Epidemiol 32:305–314
13. Caserta RA, Mariné AR, Durao MS, Silva CV, Pavao dos Santos OF, Neves HS et al (2012) A program for sustained improvement in preventing ventilator-associated pneumonia in an intensive care setting. BMC Infect Dis 12:234
14. Marini AL, Khan R, Mundekakadan S (2016) Multifaceted bundle interventions shown effective in reducing VAP rates in our multidisciplinary ICUs, BMJ Qual Improv Rep. https://doi.org/10.1136/bmjquality.u205566.w2278
15. Olgun Alcan A, Demir Korkmaz F, Uyar M (2016) Prevention of ventilator-associated pneumonia: use of the care bundle approach. Am J Infect Control 44:e173–e176
16. Talbot TR, Carr D, Parmley CL, Martin BJ, Gray B, Ambrose A et al (2015) Sustained reduction of ventilator-associated pneumonia rates using real-time course correction with a ventilator bundle compliance dashboard. Infect Control Hosp Epidemiol 36:1261–1267
17. Bouadma L, Deslandes E, Lolum I, Le Corre B, Mourvillier B, Regnier B et al (2010) Long-term impact of a multifaceted prevention program on ventilator-associated pneumonia in a medical intensive care unit. Clin Infect Dis 51:1115–1122
18. Lim KP, Kuo SW, Ko WJ, Sheng WH, Chang YY, Hong MC et al (2015) Efficacy of ventilator-associated pneumonia care bundle for prevention of ventilator-associated pneumonia in the surgical intensive care units of a medical center. J Microbiol Immunol Infect 48:316–321
19. Alvarez-Lerma F, Palomar-Martinez M, Sanchez-Garcia M, Martinez-Alonso M, Alvarez-Rodriguez I, Lorente L et al (2018) Prevention of ventilator-associated pneumonia: the multimodal approach of the spanish ICU “Pneumonia Zero” program. Crit Care Med 46:181–188
20. Li J, Xie D, Li A, Yue J (2013) Oral topical decontamination for preventing ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. J Hosp Infect 84:283–293
21. Price R, MacLennan G, Glenn J, Su DC (2014) Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ 348:g2197
22. Daneman N, Sarwar S, Fowler RA, Cuthbertson BH, Su DCSG (2013) Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis 13:328–341
23. Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963
24. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL (2000) Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162:505–511
25. Suetens C, Morales I, Savoy A, Palomar M, Hiesmayr M, Lepape A et al (2007) European surveillance of ICU-acquired infections (HELICS-ICU): methods and main results. J Hosp Infect 65:171–173
26. American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416
27. Shardell M, Harris AD, El-Kamary SS, Furuno JP, Miller RR, Perencevich EN (2007) Statistical analysis and application of quasi-experiments to antimicrobial resistance intervention studies. Clin Infect Dis 45:901–907
28. Wolkowitz M, Cooper BS, Palomar-Martinez M, Alvarez-Lerma F, Olaechea-Astigarraga P, Barnett AG et al (2014) Multilevel competing risk models to evaluate the risk of nosocomial infection. Crit Care 18:R64
29. Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D et al (1998) Incidence of and risk factors for ventilator-associated pneumonia in critically-ill patients. Ann Intern Med 129:433–440
30. Bouadma L, Wolff M, Lucet JC (2012) Ventilator-associated pneumonia and its prevention. Curr Opin Crit Care 25:285–289
31. Makris D, Luna C, Nseir S (2018) Ten ineffective interventions to prevent ventilator-associated pneumonia. Intensive Care Med 44:83–86
32. Olearo F, Albrich WC, Vernaz N, Harbarth S, Kronenberg A, Anress Swiss Centre For Antibiotic Resistance (2016) Staphylococcus aureus and methicillin resistance in Switzerland: regional differences and trends from 2004 to 2014. Swiss Med Wkly 146:w14339
33. Ammerlaan HS, Harbarth S, Buiting AG, Crook DW, Fitzpatrick F, Hanberger H et al (2013) Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis 56:798–805